0001654954-26-005002
SEC filingRevenue halved to $1.2M due to Bioprocessing Systems cost reductions, but operating loss narrowed 7.9% to -$1.7M on expense discipline.
Revenue for Q1 FY2026 dropped 49.0% year-over-year to $1.2M, primarily due to cost reductions related to the Bioprocessing Systems operations and corporate expenses, as noted in the filing. This was not a demand-driven decline but a strategic pullback as the company restructures its operations to stem losses. The prior-year quarter benefited from higher activity in that segment, making the comparison particularly stark.
Gross profit fell 53.8% to $469.9K, resulting in a gross margin of 38.3%. The margin compression reflects lower revenue absorption of fixed costs, as the decline in sales outpaced the reduction in cost of goods sold. The company's cost reduction efforts have not fully offset the impact of lower volume on profitability.
Management states that to continue as a going concern, the company will need to continue decreasing expenses, materially increase revenues, and/or secure additional external capital resources. Based on management's current operating plan, the company believes its cash on hand, including investments, is sufficient to fund operations for at least one year subsequent to the issuance of the financial statements. The company's ability to achieve profitability remains dependent on successful execution of its restructuring and growth initiatives.